IR
ITCI icon

Invictus RG’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Invictus RG’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-17,179
Closed -$259K – 859
2016
Q4 		$259K Buy
+17,179
New +$243K 0.17% 234

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Hillhouse Investment Management
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Invictus RG's ITCI Position: Q1 2017 in Review

Invictus RG sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2017, closing a stake of 17,179 shares — an estimated $259K sold.

Invictus RG first reported a position in ITCI in Q4 2016 and held it in 1 quarter. The position peaked at $259K in Q4 2016. 117 funds tracked by Wall St. Rank hold ITCI as of Q1 2017.

  • Invictus RG reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2017 after selling out during the quarter.
  • Invictus RG sold 17,179 Intra-Cellular Therapies Inc. shares in Q1 2017, an estimated $259K.
  • Invictus RG first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 1 quarter.
  • Invictus RG's Intra-Cellular Therapies Inc. position peaked at $259K in Q4 2016.
  • 117 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2017.

Based on Invictus RG's 13F filing for Q1 2017, filed 12 May 2017.